Výsledky vyhledávání - "J. A. Stakkestad"

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study

Autor: A. Kenwright, P. Lakatos, Robert R. Recker, J. A. Stakkestad, Bente Juel Riis, Jean-Yves Reginster, Paul D. Miller, Roman S. Lorenc, Edward Czerwiński, Daiva Masanauskaite

Publikováno v: Osteoporosis International. 23:1747-1756

The long-term efficacy and safety of once-monthly ibandronate were studied in this extension to the 2-year Monthly Oral Ibandronate in Ladies (MOBILE) trial. Over 5 years, lumbar spine bone mineral density (BMD) increased from baseline with monthly i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9cf7181ef51a54310a0d1d2f241e8b5
https://doi.org/10.1007/s00198-011-1773-0

Zobrazit plný text záznamu

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

Autor: Robert R. Recker, Claus Christiansen, Daiva Masanauskaite, Penelope Ward, Dieter Felsenberg, Jean-Yves Reginster, Silvano Adami, Pierre D. Delmas, Roberto Civitelli, J. A. Stakkestad, C. Hughes, Marc K. Drezner, Philip N. Sambrook, Cezary Strugala, M. A. Bolognese, David M. Reid

Publikováno v: Arthritis & Rheumatism. 54:1838-1846

Objective Although oral bisphosphonates are effective treatments for postmenopausal women with osteoporosis, oral dosing may be unsuitable for some patients. An efficacious intravenously administered bisphosphonate could be beneficial for such patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3514da722ef2112af9af2e99c5f2059
https://doi.org/10.1002/art.21918

Zobrazit plný text záznamu

Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study

Autor: B. Bonvoisin, Pierre D. Delmas, David L. Kendler, N. Mairon, Robert R. Recker, M. A. Bolognese, Dieter Felsenberg, Michael R. McClung, J. A. Stakkestad, Paul D. Miller, Jean-Yves Reginster, Cyrus Cooper, Marjorie M. Luckey, Liviu Macovei, E. Michael Lewiecki, C. Hughes

Publikováno v: Journal of Bone and Mineral Research. 20:1315-1322

Once-monthly (50/50, 100, and 150 mg) and daily (2.5 mg; 3-year vertebral fracture risk reduction: 52%) oral ibandronate regimens were compared in 1609 women with postmenopausal osteoporosis. At least equivalent efficacy and similar safety and tolera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ab7977a0745adeaa1a78e340f0becf8
https://doi.org/10.1359/jbmr.050313

Zobrazit plný text záznamu

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

Autor: J. A. Stakkestad, Robert R. Recker, Claus Christiansen, P Mahoney, Arne Hoiseth, R. C. Schimmer, Mark P. Ettinger, Pierre D. Delmas, Charles H. Chesnut, A. Skag

Publikováno v: Bone. 34:890-899

Less frequent bisphosphonate dosing in women with postmenopausal osteoporosis has the potential to promote therapy adherence through improved convenience. Ibandronate is a highly potent nitrogen-containing bisphosphonate, proven to significantly incr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541ce0b43c9120a0d6286c53cb556aa1
https://doi.org/10.1016/j.bone.2004.01.008

Zobrazit plný text záznamu

Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis

Autor: Charles H. Chesnut, Robert R. Recker, Hermann Josef Huss, R. C. Schimmer, Claus Christiansen, J. A. Stakkestad, Pierre D. Delmas, Arne Hoiseth, Jennifer Gilbride, Dieter Felsenberg, Arne Skag

Publikováno v: Journal of Bone and Mineral Research. 19:1241-1249

Oral daily (2.5 mg) and intermittent ibandronate (between-dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral fracture. Significant reduction in incident vertebral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69db461d84b6e4638ddc7afec414262c
https://doi.org/10.1359/jbmr.040325

Zobrazit plný text záznamu

Adverse effects of a SERM (Levormeloxifene)

Autor: J. A. Stakkestad, Claus Christiansen, C Christoffersen, Bente Juel Riis, L Warming, Pierre D. Delmas

Publikováno v: Maturitas. 44:189-199

Objective: Levormeloxifene is a selective estrogen receptor modulator (SERM). The development of the drug was discontinued due to intolerable adverse effects. This paper follow-up on the adverse events in a group of 234 women that was followed for 12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b29d3b684724cd096f72e791ec7e6660
https://doi.org/10.1016/s0378-5122(02)00342-0

Zobrazit plný text záznamu

Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy1

Autor: J. A. Stakkestad, C. Christiansen, Pierre D. Delmas, Peter Alexandersen, Bente Juel Riis

Publikováno v: The Journal of Clinical Endocrinology & Metabolism. 86:755-760

Three hundred and one healthy women between 45 and 65 yr of age and at least 1 yr postmenopausal were randomly assigned to 12-month double-blind therapy with levormeloxifene [1.25 (n = 51), 5, 10, or 20 mg/day], low dose continuous combined hormone r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5325e898ed68ef3329298548599ca8b9
https://doi.org/10.1210/jcem.86.2.7214

Zobrazit plný text záznamu

Use and usefulness of laboratory handbooks

Autor: A. Åsberg, Sverre Sandberg, K. S. Bjerve, J. A. Stakkestad, I. Runde

Publikováno v: Scandinavian Journal of Clinical and Laboratory Investigation. 57:647-653

The aim of this study was to investigate how reference handbooks distributed by hospital laboratories are used by medical doctors, and to what extent this kind of information can influence or change doctors' work habits. We also wanted to see if book

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2646058d62bfbffc47ffd91eb4b46cc8
https://doi.org/10.3109/00365519709055289

Zobrazit plný text záznamu

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

Autor: Roman S. Lorenc, Colin Neate, Farhad Sedarati, Peter L. Lakatos, Jean-Yves Reginster, J. A. Stakkestad

Publikováno v: Clinical rheumatology. 27(8)

Oral ibandronate is the first bisphosphonate licensed for once-monthly treatment of postmenopausal osteoporosis. The 2-year Monthly Oral iBandronate In LadiEs (MOBILE) registration study assessed bone mineral density (BMD) and markers of bone turnove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70802b98ef858d35ab1d5380d2e49ec
https://pubmed.ncbi.nlm.nih.gov/18180976

Zobrazit plný text záznamu

A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate

Autor: Cyrus Cooper, M. A. Bolognese, Michael R. McClung, Jean-Yves Reginster, Robert R. Recker, B. Bonvoisin, David L. Kendler, J. A. Stakkestad, Silvano Adami, Paul D. Miller, Roberto Civitelli, Dieter Felsenberg, Etienne Dumont, Pierre D. Delmas

Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has promp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22f488d9f60b4ccfe80c680fdf9dc5b0
http://hdl.handle.net/11562/306453

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání